FDA grants priority review to Roche’s atezolizumab in urothelial carcinoma
The US Food and Drug Administration (FDA) has accepted Roche’s Biologics License Application (BLA) and granted priority review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC).
Click on this link for more information.
